BMC333 / Evogene - LARVOL DELTA

Evogene Reports First Quarter 2023 Financial Results (PRNewswire) - "BMC333, the IBD (inflammatory bowel disease) program, has completed the pre-clinical phase. Biomica has plans to progress to a phase-1 clinical trial in the United States in 2024 and is currently scaling up manufacturing. BMC426, the IBS (irritable bowel syndrome) program, is progressing well in the pre-clinical phase."

New P1 trial • Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital (PRNewswire) - "Biomica Ltd...announced that it has closed a financing round of $20 million....The $20 million investment enables Biomica to forge ahead with developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial; scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD); as well as advance additional programs."

Financing • Genito-urinary Cancer • Immunology • Inflammatory Bowel Disease • Kidney Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Thoracic Cancer • Ulcerative Colitis • Urothelial Cancer

Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBD (ECCO-IBD 2023) - "These findings are consistent with our previously reported in vivo studies and provide a strong rationale for further development of BMC333 as an effective treatment for IBD. in vivo"

Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • IFNG • IL10

Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics (Yahoo News) - "Biomica Ltd...announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities....The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to...scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD); as well as advance additional programs."

Financing • Immunology • Inflammatory Bowel Disease

ANTI-INFLAMATORY EFFECT OF A RATIONALLY-DESIGNED LIVE BACTERIAL CONSORTIUM BASED ON MICROBIOME FUNCTIONAL GENOMIC ANALYSIS FOR TREATMENT OF IBD (DDW 2022) - "BMC333 has demonstrated promising effect in reducing inflammation and mucosal tissue damage in a mouse model of DSS-induced colitis. Further investigations of BMC333 in immunological mouse models of IBD are underway."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Ulcerative Colitis

Evogene Reports Fourth Quarter and Full Year 2021 Financial Results (PRNewswire) - "Evogene Ltd...announced today its financial results for the fourth quarter and full year of 2021, ended December 31, 2021....Milestone for 2022 – initiate scale-up for GMP production of BMC333 as preparation for clinical trials."

Commercial • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program (PRNewswire) - "Biomica...a subsidiary of Evogene Ltd...reported today positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstrated efficacy in several studies in reducing inflammation for the treatment of IBD...Looking forward, Biomica expects to begin the scale-up development processes of BMC333 in 2022, in preparation for the production of an initial clinical batch."

Preclinical • Immunology • Inflammatory Bowel Disease